Last $1.82 USD
Change Today -0.05 / -2.67%
Volume 53.6K
PTIE On Other Exchanges
Symbol
Exchange
PTIE is not on other exchanges.
As of 12:50 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

pain therapeutics inc (PTIE) Snapshot

Open
$1.88
Previous Close
$1.87
Day High
$1.89
Day Low
$1.81
52 Week High
06/26/14 - $6.22
52 Week Low
10/27/14 - $1.61
Market Cap
83.3M
Average Volume 10 Days
274.4K
EPS TTM
$0.49
Shares Outstanding
45.8M
EX-Date
12/13/12
P/E TM
3.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for PAIN THERAPEUTICS INC (PTIE)

pain therapeutics inc (PTIE) Related Businessweek News

No Related Businessweek News Found

pain therapeutics inc (PTIE) Details

Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs. Its lead drug candidate is REMOXY (oxycodone) Extended-Release Capsules CII, an investigational drug with a controlled release formulation of oxycodone for patients with moderate-to-severe chronic pain. The company’s other product candidates comprise hydromorphone, hydrocodone, and oxymorphone, which are abuse-resistant opioid product candidates. Pain Therapeutics, Inc. has strategic alliance with Pfizer, Inc. to develop and commercialize REMOXY and other abuse-resistant opioid painkillers. The company was founded in 1998 and is based in Austin, Texas.

8 Employees
Last Reported Date: 02/5/14
Founded in 1998

pain therapeutics inc (PTIE) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $366.3K
Chief Operating Officer, Chief Medical Office...
Total Annual Compensation: $373.5K
Independent Consultant and Member of Scientif...
Total Annual Compensation: $323.5K
Compensation as of Fiscal Year 2013.

pain therapeutics inc (PTIE) Key Developments

Pain Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Pain Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $3.5 million, or $0.08 per basic and diluted share, compared to a net loss of $0.8 million, or $0.02 per basic and diluted share in last year. The company reported operating loss of $3.5 million compared to $0.8 million for the last year. For the nine months, the company reported net loss of $10.2 million, or $0.23 per basic and diluted share, compared to a net loss of $1.5 million, or $0.03 per basic and diluted share and operating loss of $10.3 million compared to $1.5 million for the last year.

Pain Therapeutics Inc. - Special Call

To discuss regain of full rights to REMOXY

Pfizer to Discontinue Agreement on REMOXY(TM) (oxycodone) Extended-Release Capsules CII with Pain Therapeutics

Pfizer Inc. has notified Pain Therapeutics Inc. that it has decided to discontinue its agreement to develop and commercialize REMOXY(TM) (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer will return all rights, including responsibility for regulatory activities, to Pain Therapeutics Inc. Pfizer has concluded an internal review of the top-line results of five recently completed clinical studies required to address the Complete Response Letter received in June 2011 from the U.S. Food and Drug Administration (FDA). Pfizer and Pain Therapeutics Inc. will work together for an orderly transition of REMOXY to Pain Therapeutics Inc. Pfizer will continue ongoing activities under the agreement for the next six months until the scheduled termination date.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTIE:US $1.82 USD -0.05

PTIE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTIE.
View Industry Companies
 

Industry Analysis

PTIE

Industry Average

Valuation PTIE Industry Range
Price/Earnings 3.8x
Price/Sales 2.4x
Price/Book 2.1x
Price/Cash Flow 3.8x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAIN THERAPEUTICS INC, please visit www.paintrials.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.